{"id":24392,"date":"2026-06-22T21:00:00","date_gmt":"2026-06-22T19:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=dbcc368a8aac92eb0161e417d64eb49a"},"modified":"2026-06-22T21:00:00","modified_gmt":"2026-06-22T19:00:00","slug":"aelis-farma-availability-of-the-description-of-the-share-buyback-program","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=24392","title":{"rendered":"Aelis Farma: Availability of the Description of the Share Buyback Program"},"content":{"rendered":"

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News:<\/p><\/a><\/a>

\nAelis Farma <\/b>(ISIN: FR0014007ZB4 \u2013 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1<\/sub> receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026.<\/p>

\nPursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on June 3, 2026, in its 12th<\/sup> resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law.<\/p>

\nIn accordance with Article 241-3 of the General Regulation of the Autorit\u00e9 des March\u00e9s Financiers<\/i> (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 23, 2026, under number D.26-0284.\nThis document is available on the Company's website at: https:\/\/www.aelisfarma.com\/investors<\/a>.<\/p>

\n***<\/p>

\nAbout AELIS FARMA<\/b><\/p>

\nFounded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1<\/sub> receptor of the endocannabinoid system (CB1<\/sub>-SSi). CB1<\/sub>-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1<\/sub> hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company\u2019s CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1<\/sub>-SSi appear to selectively inhibit the disease-related activity of the CB1<\/sub> receptor without disrupting its normal physiological activity. CB1<\/sub>-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.<\/p>

\nAelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1\/2 to be safe and able to improve adaptive behavior in young adults with Down syndrome (Trisomy 21) and has started a Phase 2b in Europe aiming to confirm its efficacy and safety in people with Down syndrome. The clinical results obtained with these 2 compounds have confirmed the safety and therapeutic activity of CB1<\/sub>-SSi in humans. The Company also develops a portfolio of new innovative CB1<\/sub>-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1<\/sub> receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The new drugs developed by the Company belong to the same general pharmacological class, the CB1<\/sub>-SSi, but have distinct functional effects allowing them to target different types of dysregulations of the CB1<\/sub> receptor and guaranteeing that the different compounds are not substitutable one with the others.<\/p>

\nFor more information, visit www.aelisfarma.com<\/a> and follow us on LinkedIn<\/a> and Twitter<\/a>.<\/p>

\nISIN: FR0014007ZB4\nTicker: AELIS\nC Compartment of Euronext Paris<\/p>

\nDisclaimer<\/b><\/p>

\nForward-looking statements<\/b><\/p>

\nSome information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 \"Risk Factors\" of Aelis Farma's Universal Registration Document filed with the Autorit\u00e9 des March\u00e9s Financiers<\/i> on April 23, 2026, under number D.26-0284.<\/p>

\nThese forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.<\/p> Contacts<\/b>

\nAELIS FARMA<\/b>Pier Vincenzo Piazza\nChief Executive Officer\ncontact@aelisfarma.com<\/a><\/p>

\nNewCap<\/b>Dusan Oresansky\nInvestor Relations\naelis@newcap.eu<\/a>+33 1 44 71 94 92<\/p>","protected":false},"excerpt":{"rendered":"

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News:
\nAelis Farma (ISIN: FR0014007ZB4 \u2013 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor,…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24392","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24392"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24392\/revisions"}],"predecessor-version":[{"id":24393,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/24392\/revisions\/24393"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}